Recently, several studies have investigated the role of 68Ga-PSMA PET/CT in a first-line diagnostic setting and especially in patients with high-risk and biochemically recurrent PCa [11, 12]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.